International Journal of Pharmaceutics

International Journal of Pharmaceutics is a pharmaceutical science journal published by Elsevier, established in 1978 and covering the design, manufacture and evaluation of drug delivery systems, and its 2025 impact factor is 6.0.（International Journal of Pharmaceutics）是 Elsevier 出版的药学科学期刊，1978 年创刊，涵盖药物递送系统的设计、制造与评价，2025 年影响因子为 6.0。

Scope

• It serves pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals.该刊面向关注药物、疫苗与生物制品之器械与递送系统的物理、化学与生物学性质的药学科学家。
• It covers the design, manufacture and evaluation of such delivery systems.涵盖此类递送系统的设计、制造与评价。
• This includes the evaluation of drug properties, excipients such as surfactants and polymers, and novel materials.这包括药物性质、表面活性剂与聚合物等辅料以及新型材料的评价。
• The journal has special sections on pharmaceutical nanotechnology and personalized medicines.该刊设有药物纳米技术与个体化医疗专题板块。
• It publishes research papers, reviews, commentaries, letters to the editor and special issues.发表研究论文、综述、评论、致编辑信与专刊。

History

• The journal was established in 1978, with its first issue appearing in January and February 1978.该刊 1978 年创刊，首期于 1978 年 1 至 2 月出版。
• It was originally published by Elsevier and North-Holland Biomedical Press.最初由（Elsevier）与（North-Holland Biomedical Press）出版。
• It is now published by Elsevier.现由 Elsevier 出版。
• It is issued in about thirty-nine parts a year as a hybrid open-access journal and recorded a 2025 impact factor of 6.0.该刊每年出版约 39 期，实行混合开放获取，2025 年影响因子为 6.0。

Editors

• The Editor-in-Chief is Juergen Siepmann of the University of Lille in France.现任主编为法国（University of Lille）的 Juergen Siepmann。
• Regional editors include Zhengrong Cui for North America and Kiyohiko Sugano for Japan and the Far East.区域编辑包括负责北美事务的 Zhengrong Cui 与负责日本及远东事务的 Kiyohiko Sugano。
• Editors also include Abdul Basit, Yongzhuo Huang, Sara Nicoli and Mingshi Yang.编辑还包括 Abdul Basit、Yongzhuo Huang、Sara Nicoli 与 Mingshi Yang。
• The overriding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience, and routine bioequivalence studies are unlikely to be accepted.录用首要标准是原创性、高科学质量与对多学科读者的意义，常规生物等效性研究通常难以被接受。